Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder
- 1 February 2017
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 113, 60-70
Abstract
No abstract availableKeywords
Funding Information
- NIH (AA022448)
- USC School of Pharmacy
This publication has 52 references indexed in Scilit:
- Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectinInternational Journal of Neuropsychopharmacology, 2013
- Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disordersProceedings of the National Academy of Sciences, 2010
- CRF-1 Antagonist and CRF-2 Agonist Decrease Binge-Like Ethanol Drinking in C57BL/6J Mice Independent of the HPA AxisNeuropsychopharmacology, 2010
- Hybrid Mice as Genetic Models of High Alcohol ConsumptionBehavior Genetics, 2009
- Ethanol intake patterns in female mice: Influence of allopregnanolone and the inhibition of its synthesisDrug and Alcohol Dependence, 2008
- Ethanol Facilitates Glutamatergic Transmission to Dopamine Neurons in the Ventral Tegmental AreaNeuropsychopharmacology, 2008
- Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptorsNeuropharmacology, 2008
- Voluntary ethanol consumption in 22 inbred mouse strainsAlcohol, 2008
- Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seekingProceedings of the National Academy of Sciences, 2007
- Ivermectin, an Unconventional Agonist of the Glycine Receptor Chloride ChannelJournal of Biological Chemistry, 2001